PRESS RELEASE
By: News Direct
December 9, 2024
PathAI Launches AIM-IHC Breast Panel on AISight® Platform to Streamline Breast Cancer Biomarker Quantification and Improve Pathologist Efficiency
PathAI, a leader in AI-powered pathology solutions, today announced the launch of the AIM-IHC Breast Panel, a set pf advanced AI-assisted, algorithms designed to quantify critical breast cancer biomarkers—HER2, ER, PR, and Ki-67. Available now on the AISight® Image Management System (IMS), this comprehensive panel provides partners with accurate, consistent scoring, enhancing precision and streamlining workflow efficiency. Adding to the existing AIM-HER2 Breast solution, this consolidation of critical breast cancer biomarker algorithms into a single, pathologist-centric image management system directly addresses the need for standardized, reliable quantification assist tools to support pathologists.
PathAI’s AIM-IHC Breast Panel is designed to address key challenges in breast cancer biomarker quantification, particularly the need for precise and reproducible assessment. The panel provides accurate, consistent, zero-click scoring for HER2, ER, PR, and Ki-67 directly from routine immunohistochemistry (IHC) images. With automated tissue segmentation and detection of on-slide controls, the panel classifies areas of invasive versus non-invasive cancer and provides overlays to support algorithmic scoring. This breast cancer-centric panel is designed for a pathologist-assist workflow, allowing users to better differentiate regions of interest, improve the accuracy of invasive cancer segmentation, and streamline tedious scoring processes.
The AIM-IHC Breast Panel is the latest addition to PathAI's expanding suite of AI-powered solutions on the AISight® IMS. AISight serves as a central hub for managing pathology images, enabling seamless integration of various AI-driven tools for pathology labs. By centralizing workflows and offering a growing portfolio of applications, PathAI empowers pathologists and researchers to improve precision and efficiency, all within a unified, cloud-native platform. This continuous expansion of the AISight IMS and the full menu of AI applications available on the platform from PathAI as well as third-party vendors underscores PathAI’s commitment to providing comprehensive, reliable tools that enhance the field of pathology and ultimately, patient outcomes.
“We are committed to advancing precision pathology with cutting-edge AI technology, empowering pathologists with the tools to make more accurate, consistent, and efficient assessments,” said Andrew Beck, CEO of PathAI. “The AIM-IHC Breast Panel is the latest step in our mission to enhance AI-powered scoring for key breast cancer biomarkers.”
In addition, the AIM-IHC Breast Panel goes beyond HER2 by offering fast and accurate Ki-67 scoring, addressing the challenges of this emerging biomarker, which has traditionally been time-consuming and labor-intensive. Pathologists no longer need to spend significant time manually counting cells or rely on imprecise approximations. The panel’s automated features, such as classifying invasive cancer and generating percentage-based results for positive cancer cells, provide pathologists with the clarity needed to produce more accurate scoring.
The introduction of the AIM-IHC Breast Panel marks a significant step in PathAI’s ongoing mission to enable precision pathology and empower pathologists with the latest AI-driven technologies. This release highlights PathAI’s commitment to improving workflow efficiency, speed, and assessment accuracy. As the AISight® Image Management System continues to expand with new solutions, pathologists gain access to a comprehensive suite of tools that streamline their workflow, accelerating decision-making and reducing time spent on manual tasks. With each of our new advancements, pathologists are better equipped to deliver precise, actionable insights for cancer diagnostic research.
Footnotes
AIM-IHC Breast Panel, AIM-HER2, AIM-ER, AIM-PR, and AIM-Ki-67 are for research use only. Not for use in diagnostic procedures.
AISight is for Research Use Only in the US; AISight Dx is CE-IVD marked in Europe, UK and Switzerland.
About PathAI
PathAI is a global leader in AI-powered digital pathology solutions, dedicated to improving operational efficiency in pathology labs worldwide. Through its innovative technology and strategic partnerships, PathAI is shaping the future of medical diagnostics and advancing patient care across the globe.
Contact DetailsSVM Public Relations and Marketing Communications
+1 401-490-9700
Company WebsiteView source version on newsdirect.com: https://newsdirect.com/news/pathai-launches-aim-ihc-breast-panel-on-aisight-r-platform-to-streamline-breast-cancer-biomarker-quantification-and-improve-pathologist-efficiency-183049207
This press release is distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is PathAI Launches AIM-IHC Breast Panel on AISight® Platform to Streamline Breast Cancer Biomarker Quantification and Improve Pathologist Efficiency.